Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.
You may also be interested in...
Vaccine spending projections represent about 2% of total spending on medicines IQVIA said. Increased spending will be partly offset by COIVD-19 disruptions, however.
"I don't know why folks are anxious to have a race to the top in terms of rates," Joseph Wolk ways. After US tax reform in 2017, lowering the standard tax rate from 35% to 21%, J&J committed to increasing US investment 15% over the next four years.
J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.